Venture Life Group (VLG) Transition period summary

Executive summary

• Completed transformation into a pure-play consumer healthcare business, divesting CDMO and non-core oral care brands for significant value.

• Achieved 16% proforma revenue growth over the 17-month period, driven by volume and new product launches.

• Expanded US presence with the acquisition of FemiClear and CUROXEN, providing a platform for further growth.

• CEO succession announced: Jerry Randall to retire, succeeded by CFO Danny Wells from January 2027.

Financial highlights

• Revenue from continuing operations rose to £50.0m (2024: £26.6m), with gross profit at £22.3m and gross margin at 44.6%.

• Adjusted EBITDA increased to £7.9m (2024: £6.2m), but margin declined to 15.7% due to temporary de-leveraging.

• Group profit after tax was £3.4m (2024: £0.3m loss), including £7.2m profit from discontinued operations.

• Adjusted diluted EPS for the group rose to 14.74p (2024: 3.65p); diluted EPS at 2.70p (2024: -0.25p).

• Cash reserves at £11.5m with no drawn debt, after funding acquisitions and share buybacks.

Outlook and guidance

• Confident in meeting market expectations for FY27 and beyond, with aspirations to exceed £300m annual revenue and 25% adjusted EBITDA margin within five years.

• Focused on organic growth, disciplined M&A, and expansion in Women's Intimate Health and Hormonal Health segments in the UK and US.